PD TFEB Activator and Lysosomal Biogenesis Companies

Migration, Crosslink

📖

PD TFEB Activator and Lysosomal Biogenesis Companies

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-pd-tfeb-activator-compani

📖 Wiki Page

company823 wordssynced 2026-04-02

Overview

This category covers biotechnology and pharmaceutical companies developing TFEB (Transcription Factor EB) activators and lysosomal biogenesis therapeutics for Parkinson's disease. These approaches target the master regulatory pathway for cellular clearance, enhancing the cell's ability to clear toxic protein aggregates, damaged mitochondria, and lipid deposits through enhanced autophagy and lysosomal function.

TFEB is the master regulator of the CLEAR (Coordinated Lysosomal Expression and Regulation) network. In Parkinson's disease, TFEB activity is suppressed due to hyperactive mTORC1 signaling, which keeps TFEB phosphorylated and sequestered in the cytoplasm. This impairs the cell's ability to clear alpha-synuclein aggregates and contributes to neurodegeneration.

Pathway / Mechanism Diagram

graph TD A["mTORC1 Active"] --> B["TFEB Phosphorylation"] B --> C["TFEB Cytoplasmic Retention"] D["Starvation / Lysosomal Stress"] --> E["mTORC1 Inhibition"] E --> F["Calcineurin Activation"] F --> G["TFEB Dephosphorylation"] G --> H["TFEB Nuclear Translocation"] H --> I["CLEAR Network Activation"] I --> J["Lysosomal Biogenesis"] I --> K["Autophagy Genes"] I --> L["Lipid Catabolism"] J --> M["Enhanced Aggregate Clearance"] K --> M M --> N["Abeta and Tau Clearance"] N --> O["Neuroprotection"] style H fill:#1b5e20,color:#e0e0e0 style O fill:#1b5e20,color:#e0e0e0 style C fill:#5d4400,color:#e0e0e0

Key Companies

TFEB Activation and Autophagy Enhancement

...

Overview

This category covers biotechnology and pharmaceutical companies developing TFEB (Transcription Factor EB) activators and lysosomal biogenesis therapeutics for Parkinson's disease. These approaches target the master regulatory pathway for cellular clearance, enhancing the cell's ability to clear toxic protein aggregates, damaged mitochondria, and lipid deposits through enhanced autophagy and lysosomal function.

TFEB is the master regulator of the CLEAR (Coordinated Lysosomal Expression and Regulation) network. In Parkinson's disease, TFEB activity is suppressed due to hyperactive mTORC1 signaling, which keeps TFEB phosphorylated and sequestered in the cytoplasm. This impairs the cell's ability to clear alpha-synuclein aggregates and contributes to neurodegeneration.

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Key Companies

TFEB Activation and Autophagy Enhancement

Lyterian Therapeutics

Focus: mTOR-independent TFEB activation and autophagy enhancement
Lead Candidate: LT-002
Indication: Parkinson's disease
Stage: Preclinical
Mechanism: Small molecule activators that promote TFEB nuclear translocation without mTOR inhibition
Page: [Lyterian Therapeutics](/companies/lyterian-therapeutics)

Iduna Biotechnology

Focus: Chaperone-mediated autophagy (CMA) enhancement with TFEB modulation
Lead Candidate: IDU-101
Indication: Parkinson's disease
Stage: IND-enabling
Mechanism: LAMP2A agonists that enhance CMA and promote TFEB activity for synergistic lysosomal enhancement
Page: [Iduna Biotechnology](/companies/iduna-biotechnology)

Lysoway Therapeutics

Focus: Lysosomal ion channel modulators (TRPML1, TMEM175 agonists)
Lead Candidates: LY-001 (TRPML1), LY-002 (TMEM175)
Indication: Parkinson's disease, Alzheimer's disease
Stage: Preclinical/Discovery
Mechanism: Small molecule agonists of lysosomal cation channels to enhance autophagy-lysosomal function through calcium signaling, which intersects with TFEB pathway activation
Page: [Lysoway Therapeutics](/companies/lysoway-therapeutics)

Heqix Therapeutics

Focus: Autophagy induction through mTOR modulation
Lead Candidate: HQX-001
Indication: Parkinson's disease
Stage: Discovery
Mechanism: mTOR modulators to enhance autophagy and lysosomal function, leading to TFEB activation
Page: [Heqix Therapeutics](/companies/heqix-therapeutics)

Autophagy Enhancement (TFEB-Adjacent)

Retro Biosciences

Focus: Macroautophagy enhancement
Lead Candidate: RB-001
Indication: Alzheimer's disease (Phase 1), Parkinson's disease (preclinical)
Stage: Phase 1
Mechanism: Small molecule enhancers of macroautophagy to clear protein aggregates and damaged organelles
Page: [Retro Biosciences](/companies/retro-biosciences)

Pipeline Summary

| Company | Drug | Mechanism | Phase | Indication |
|---------|------|-----------|-------|----------|
| Lyterian Therapeutics | LT-002 | TFEB activation (mTOR-independent) | Preclinical | PD |
| Iduna Biotechnology | IDU-101 | CMA/LAMP2A + TFEB | IND-enabling | PD |
| Lysoway Therapeutics | LY-001 | TRPML1 agonist | Preclinical | PD/AD |
| Heqix Therapeutics | HQX-001 | mTOR modulation | Discovery | PD |
| Retro Biosciences | RB-001 | Autophagy enhancer | Phase 1 | AD/PD |

Therapeutic Mechanisms

TFEB Activation Approaches

mTOR Inhibition: Rapamycin, Torin 1 — blocks mTORC1 to release TFEB (but has broad effects)

mTOR-Independent TFEB Activation: Lyterian LT-002 — directly promotes TFEB nuclear translocation without broad mTOR inhibition

CMA Enhancement with TFEB Modulation: Iduna IDU-101 — enhances LAMP2A-mediated CMA while promoting TFEB activity

Lysosomal Calcium Signaling: Lysoway LY-001 — TRPML1 activation triggers calcineurin-dependent TFEB dephosphorylation

Lysosomal Biogenesis

TFEB activates transcription of genes involved in:

Lysosomal enzymes (CTSA, GAA, GBA)
Autophagy proteins (ATG9, LC3, p62)
Lysosomal membrane proteins (LAMP1, LAMP2)
Lipid metabolism (PLIN3, LIPG)

Scientific Rationale

TFEB Dysfunction in Parkinson's Disease

mTORC1 Hyperactivity: Increased mTORC1 activity sequesters TFEB in the cytoplasm
Nuclear Localization Deficit: TFEB nuclear translocation is impaired in PD neurons
Impaired Clearance: Reduced lysosomal biogenesis compromises protein aggregate clearance
Bidirectional Relationships: Alpha-synuclein accumulation further impairs TFEB function

Advantages of TFEB-Targeted Approach

Master Regulator: Single target enhances multiple clearance pathways

Physiological: Restores natural cellular mechanisms rather than imposing artificial pathways

Synergistic: Enhances autophagy, lysosomal function, and mitochondrial quality control simultaneously

Disease-Modifying: Addresses root cause rather than symptoms

Research Context

Key Findings Supporting TFEB Activation

Preclinical Evidence: TFEB activation reduces alpha-synuclein pathology in mouse models

Genetic Evidence: TFEB overexpression protects dopaminergic neurons

Patient Data: TFEB nuclear localization is reduced in PD patient brains

Combination Potential: TFEB activators synergize with GBA modulators, LRRK2 inhibitors

Clinical Development Challenges

Brain Penetration: Achieving adequate CNS exposure remains challenging

Selectivity: mTOR-independent activation preferred to avoid immunosuppressive effects

Biomarkers: Need for biomarkers to monitor target engagement

Dosing: Balancing efficacy with safety requires careful optimization

Cross-Links

[TFEB Activators for Parkinson's Disease](/mechanisms/tfeb-activators-parkinsons)
[Autophagy-Lysosome Pathway in Parkinson's Disease](/mechanisms/autophagy-lysosomal-pathway-parkinsons)
[Lysosomal Dysfunction in Parkinson's Disease](/mechanisms/lysosomal-dysfunction)
[Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy-neurodegeneration)
[Parkinson's Disease Pathways](/mechanisms/parkinsons-disease-pathways)
[PD Lysosomal Autophagy Companies](/companies/pd-lysosomal-autophagy-companies)

[TFEB](/entities/tfeb) — Master regulator of lysosomal biogenesis
[Autophagy](/entities/autophagy) — Primary target pathway
[Lysosomes](/entities/lysosomes) — Target organelle
[mTOR Signaling](/mechanisms/mtor-signaling-pathway) — Regulatory pathway
[LAMP2A](/proteins/lamp2a-protein) — CMA receptor
[TRPML1](/proteins/trpml1-protein) — Lysosomal calcium channel

[Lyterian Therapeutics](/companies/lyterian-therapeutics)
[Iduna Biotechnology](/companies/iduna-biotechnology)
[Lysoway Therapeutics](/companies/lysoway-therapeutics)
[Heqix Therapeutics](/companies/heqix-therapeutics)
[Retro Biosciences](/companies/retro-biosciences)
[Gain Therapeutics](/companies/gain-therapeutics)
[Denali Therapeutics](/companies/denali-therapeutics)

External Links

[Lyterian Therapeutics](https://www.lyterian.com)
[Iduna Biotechnology](https://www.idunabio.com)
[Lysoway Therapeutics](https://www.lysoway.com)
[Heqix Therapeutics](https://www.heqix.com)
[Retro Biosciences](https://www.retrobio.com)
[Michael J. Fox Foundation](https://www.michaeljfox.org)
[Parkinson's Foundation](https://www.parkinson.org)

References

[TFEB Activators for Parkinson's Disease Mechanism](/mechanisms/tfeb-activators-parkinsons)

[Lyterian Therapeutics Website](https://www.lyterian.com)

[Iduna Biotechnology Website](https://www.idunabio.com)

[Lysoway Therapeutics Website](https://www.lysoway.com)

[Heqix Therapeutics Website](https://www.heqix.com)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD TFEB Activator and Lysosomal Biogenesis Companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

companies-pd-tfeb-activator-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-pd-tfeb-activator-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5527854863bd
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-pd-tfeb-activator-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

309

Outgoing

311

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PD TFEB Activator and Lysosomal Biogenesis Companies

Overview

Pathway / Mechanism Diagram

Key Companies

TFEB Activation and Autophagy Enhancement

Overview

Pathway / Mechanism Diagram

Key Companies

TFEB Activation and Autophagy Enhancement

Lyterian Therapeutics

Iduna Biotechnology

Lysoway Therapeutics

Heqix Therapeutics

Autophagy Enhancement (TFEB-Adjacent)

Retro Biosciences

Pipeline Summary

Therapeutic Mechanisms

TFEB Activation Approaches

Lysosomal Biogenesis

Scientific Rationale

TFEB Dysfunction in Parkinson's Disease

Advantages of TFEB-Targeted Approach

Research Context

Key Findings Supporting TFEB Activation

Clinical Development Challenges

Cross-Links

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

PD TFEB Activator and Lysosomal Biogenesis Companies

Overview

Pathway / Mechanism Diagram

Key Companies

TFEB Activation and Autophagy Enhancement

Overview

Pathway / Mechanism Diagram

Key Companies

TFEB Activation and Autophagy Enhancement

Lyterian Therapeutics

Iduna Biotechnology

Lysoway Therapeutics

Heqix Therapeutics

Autophagy Enhancement (TFEB-Adjacent)

Retro Biosciences

Pipeline Summary

Therapeutic Mechanisms

TFEB Activation Approaches

Lysosomal Biogenesis

Scientific Rationale

TFEB Dysfunction in Parkinson's Disease

Advantages of TFEB-Targeted Approach

Research Context

Key Findings Supporting TFEB Activation

Clinical Development Challenges

Cross-Links

Related Mechanisms and Pathways

Related Companies

External Links

References

Pathway Diagram

💬 Discussion